Galmed Pharmaceuticals Ltd (GLMD)

NASDAQ
Currency in USD
Disclaimer
0.620
+0.058
(+10.32%)
Closed
0.616
-0.004
(-0.645%)
After Hours
Real-time Data
Day's Range
0.570
0.625
52 wk Range
0.538
14.175
Volume
42,077
Prev. Close
0.562
Open
0.576
Day's Range
0.57-0.625
52 wk Range
0.538-14.175
Volume
42,077
Average Vol. (3m)
279,791
1-Year Change
-86.85%
Shares Outstanding
2,060,232
Analysts
Technical
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
4.000
Upside +545.161%

People Also Watch

30.68
PCRX
-0.55%
7.170
FF
-0.28%
0.1921
VVOS
+5.38%
0.178
TCON
0.00%
3.0100
WE
-1.31%
How do you feel today about GLMD?
Vote to see community's results!
or

Galmed Pharmaceuticals Ltd Company Profile

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.

Income Statement